Vaccines for Tuberculosis Control

Dear Colleagues,

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the leading causes of global morbidity and mortality. Despite the Bacille Calmette–Guérin (BCG) vaccine being available for over a century, TB continues to pose a significant global health threat, especially in low- and middle-income countries. The emergence of drug-resistant Mtb strains further complicates efforts to control TB, emphasizing the necessity for long-lasting and broad-spectrum protection.

Recent advancements have transformed Mtb vaccine research. By integrating genomics, transcriptomics, and proteomics with computational modeling, bioinformatics, and artificial intelligence, researchers can now design vaccines more effectively. However, new vaccines/antigens need to be validated to ensure that they include novel immunodominant epitopes for B and T cells and macrophages. Predicting antigen–MHC binding affinities and mapping protective immune pathways are key, and data-driven and machine learning-guided approaches could expedite the discovery and optimization of next-generation TB vaccines, particularly using mRNA-based and replication-deficient viral vector platforms.

This Special Issue, titled “Vaccines for Tuberculosis Control,” aims to present recent scientific findings, insights, technological innovations, and translational approaches to transform TB vaccine development. A primary goal is to bring together high-quality original research articles and comprehensive reviews that enhance our understanding of immune mechanisms, antigen discovery, and the translational development of vaccines for TB.

We welcome original research articles, reviews, mini-reviews, and perspectives for this Special Issue. Research areas may include the following:

• Novel vaccine candidates;
• Recombinant and live-attenuated vaccine development;
• Host–vaccine interaction studies;
• New animal models for vaccine evaluation;
• Subunit, peptide, replication-deficient viral, and mRNA-based TB vaccines;
• Adjuvant immunology and delivery strategies.

We look forward to receiving your valuable contributions to this compendium, which will guide the development of new-generation TB vaccines.

Prof. Dr. Subramanian Dhandayuthapani
Prof. Dr. Chinnaswamy Jagannath
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• tuberculosis vaccine
• recombinant vaccines
• mRNA vaccines
• viral vector vaccines
• peptide vaccines
• DNA vaccines
• live-attenuated vaccines
• immunology of adjuvants
• immunoinformatics
• multi-omics integration